Carlsmed (CARL) Stock: Buy, Sell, or Hold?
CARL - Carlsmed, Inc. Common Stock
$14.73
-0.03 (-0.20%)
âŧ
5d:
-5.09%
30d:
+7.36%
90d:
+26.76%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CARL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CARL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CARL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CARL is currently trading at $14.73, which is considered fair relative to its 30-day fair value range of $13.96 to $16.20.
Technical Outlook: Technically, CARL is in a strong uptrend. The price is currently testing key support at $14.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CARL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.20 (+30.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CARL is in a strong uptrend. The price is currently testing key support at $14.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CARL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.20 (+30.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.96 -
$16.20
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.3% below Wall St target ($19.20)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.96 -
$16.20
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$14.72
Resistance Level
$17.20
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.67
Wall Street Target
$19.20
(+30.3%)
Revenue Growth (YoY)
56.7%
Profit Margin
-57.4%
Share & Embed Analysis
Last updated: September 12, 2026 9:41 PM ET
Data refreshes hourly during market hours. Next update: 10:41 PM
Data refreshes hourly during market hours. Next update: 10:41 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CARL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$294 | 39 SELL |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$32 | 42 HOLD |
|
GEHC
GE HealthCare TechnologiâĻ |
STRONG BUY
21 analysts |
$90 | 49 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$14 | 51 HOLD |
|
WAY
Waystar Holding Corp. CoâĻ |
STRONG BUY
13 analysts |
$33 | 45 HOLD |